Loading clinical trials...
Loading clinical trials...
The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Eli Lilly and Company
NCT02600949 · Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, and more
NCT07446322 · Ras-mutated Metastatic Colorectal Cancer, mCRC, and more
NCT05919264 · Cancer, Colorectal Cancer, and more
NCT07541924 · Colorectal Cancer Screening, Colonic Polyps/Colonoscopy/Colorectal Neoplasms, and more
NCT07536113 · Metastatic Colorectal Cancer (CRC)
Carolinas Medical Center
Charlotte, North Carolina
Sarah Cannon Research Institute SCRI
Nashville, Tennessee
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cologne
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions